Clinical studies on breast cancer patients found elevated IL-6 levels at both the edges of breast tumour masses and in patient’s sera as a consequence of overexpression and secretion by breast cancer cells (Hou et al., 2018; Johnson et al., 2018; Chen et al., 2022; Manore et al., 2022). This evidence concerns the gene IL6 and breast carcinoma.